Prenetics Global's IM8 brand growth

On March 24, 2026, Prenetics Global (PRE) announced a strategic partnership with Superpower, combining clinical-grade supplementation with blood diagnostics. This collaboration will enable PRE to expand its IM8 brand into the supplements market, leveraging Superpower's expertise. Previously, on March 23, PRE appointed Brian Rosin as U.S. CFO of IM8, strengthening its financial leadership.

This partnership drives PRE's expansion into a new revenue stream, potentially boosting its growth trajectory. The diagnostics and supplements sector, currently valued at $100 billion, is expected to grow at a CAGR of 7% until 2028. PRE's competitors in this space include Abbott Laboratories and Thermo Fisher Scientific.

Investors should watch for PRE's Q1 2026 earnings, due on April 15, which may provide initial insights into the impact of the Superpower partnership. Additionally, the launch of the first co-branded product, expected in Q3 2026, will be a key catalyst for assessing the partnership's success.